Login to Your Account

Competing Cholesterol-Lowering Drugs Ready for AdCom Review

By Peter Winter

Monday, September 24, 2012

There is no shortage of companies targeting the cholesterol-lowering universe with drug candidates and several novel approaches are being tested in the clinic designed to lower the levels of LDL cholesterol in patients. In less than a month the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) will meet over the course of two days to render an opinion on two of these drugs. Both target the same indication – homozygous familial hypercholesterolemia (HoFH), a rare and generally fatal disease, but each has a different mechanism of action.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription